Groundbreaking Cancer Therapy: A New Hope for MS?

At age 24, Grace Miller was a law student when a diagnosis of multiple sclerosis changed her life. For years, severe fatigue was misattributed to narcolepsy before vertigo and temporary vision loss led to the correct conclusion. Now 46 and living in Fishers, Indiana, Miller spent fifteen years on medications that made her feel ill with each dose. Her vision has fluctuated, and by 2021, she began using a cane. “I used to practice law, but now reading a book isn’t even an option,” she shared. Last year, however, she joined an early clinical trial at the Cleveland Clinic for a revolutionary cancer therapy now being explored for its potential to halt MS progression.

This treatment, known as CAR-T therapy, represents a monumental advance in oncology. The process involves extracting a patient’s own T cells, immune cells that typically combat infections, and genetically engineering them to recognize and destroy specific proteins on tumor cells. Once reinfused, these reprogrammed cells become a persistent force against cancer. It has shown remarkable success against B cell cancers like certain leukemias and lymphomas. Interestingly, rogue B cells are also central to multiple sclerosis, where they mistakenly attack myelin, the protective sheath around nerve fibers. This damage disrupts nerve signals, leading to a gradual loss of limb function, vision, and memory. While existing treatments can slow this process, none offer a cure.

Current MS medications target these overactive B cells but cannot reach those hiding within the brain and central nervous system. CAR-T cells, however, appear capable of crossing that barrier. “They would eliminate B cells in the blood, as our current antibody therapies do, but also those sequestered in the brain, which we believe are crucial to disease progression,” explained Dr. Jeffrey Cohen, director of the experimental therapeutics program at the Cleveland Clinic’s Mellen Center for Multiple Sclerosis. He leads the trial and notes that the extensive prior use of CAR-T in cancer provides a significant foundation, though he stresses all MS trials are very early exploratory studies.

Similar investigations are ongoing at institutions like Stanford University, Massachusetts General Hospital, and Columbia University. The Cleveland Clinic trial, sponsored by Bristol Myers Squibb, has enrolled four MS patients and three with myasthenia gravis. Two participants, including Miller, have progressive MS, characterized by steady neurological decline. The others have relapsing MS, marked by unpredictable attacks followed by recovery periods. The therapy typically involves a single infusion of modified cells, reprogrammed to attack overactive B cells instead of cancer, preceded by chemotherapy to clear space in the immune system. All four MS participants received their infusions between six and twelve months ago.

Miller underwent the procedure last May. Nearly a year later, she still uses a cane but is taking more steps without it. “This fall, my friend visited with her 18-month-old, and for the first time, I was able to pick up the child while standing. I’d never done that before,” Miller said. Researchers are cautiously optimistic but emphasize the preliminary nature of the work. Some experts question whether CAR-T will outperform existing treatments meaningfully. Dr. Rhonda Voskuhl of the UCLA Multiple Sclerosis Program points out that current antibodies are effective despite not penetrating the blood-brain barrier. She is skeptical about its utility in progressive MS, where inflammatory lesions slow but significant neural damage is already present. “You cannot simply anti-inflammatory your way out of a disease that involves both inflammation and neurodegeneration. We need therapies that protect and repair brain cells,” Voskuhl stated.

This sentiment is echoed by Dr. Enrique Alvarez of the Rocky Mountain MS Center, who underscores the urgent need for treatments that repair neurological damage, potentially through stem cell therapy. “No one disputes the need for regenerative approaches, but we’re not yet at a point of great success with stem cells,” Alvarez noted. He views improving existing drugs as a valuable pursuit, citing ofatumumab, an MS therapy originally for leukemia, as an example. “If CAR-T could prevent lifelong treatment dependency, that alone is worth investigating,” he added.

Dr. Cohen acknowledges that CAR-T is unlikely to repair existing MS damage, a capability desperately needed. The body possesses some innate repair mechanisms, but MS often outpaces them. “If we can inhibit the damage, natural repair might catch up,” he suggested. The therapy carries significant risks, including cytokine release syndrome, which can trigger severe flu-like symptoms and organ failure, and a neurotoxic syndrome called ICANS, a particular concern for MS patients. “There could be unforeseen complications because MS patients differ from cancer patients. It might not be effective, so caution is paramount at this stage,” Cohen warned.

Despite the uncertainties, the rapid evolution of CAR-T technology, backed by major pharmaceutical companies, promises continual refinement. These trials will clarify whether targeting B cells in the central nervous system truly alters MS progression. “Even if CAR-T fails, the insights into the immune system and MS will be invaluable,” Alvarez concluded. For patients like Grace Miller, this experimental path represents a tangible, if cautious, new hope.

(Source: NBC News)